Ductal carcinoma in situ: Treatment or active surveillance?

Expert Review of Anticancer Therapy

Volumn 15, Issue 7, 2015, Pages 777-785

  Kuerer, Henry M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

atypical ductal hyperplasia; breast cancer therapy; breast pathology; breast radiation; breast surgery; clinical trials; DCIS; ductal carcinoma in situ; prognosis; tamoxifen

Indexed keywords

CELECOXIB; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ATYPICAL DUCTAL HYPERPLASIA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DISEASE SURVEILLANCE; ECHOMAMMOGRAPHY; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; TUMOR BIOPSY; TUMOR INVASION; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLINICAL TRIAL (TOPIC); FEMALE; PATHOLOGY; PATIENT PREFERENCE; PREOPERATIVE CARE; TREATMENT OUTCOME;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PATIENT PREFERENCE; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 84933506200     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1043897     Document Type: Review

References (38)

1. Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 2009;27:279-88.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63: 11-30
3. Alvarado R, Lari SA, Roses RE, et al. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 2012;19:3777-84
4. Silverstein MJ, Lagios MD. Treatment Selection for Patients with Ductal Carcinoma In Situ (DCIS) of the Breast Using the University of Southern California/Van Nuys (USC/VNPI) Prognostic Index. Breast J 2015;21:127-32
5. Rosen PP, Braun DW Jr, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer 1980;46:919-25
6. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982;49:751-8
7. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994;11: 223-35
8. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481-4.
9. Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 2005;103:1778-84
10. Roses RE, Arun BK, Lari SA, et al. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 2011;18:2873-8
11. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103:478-88
12. Donker M, Litiere S, Werutsky G, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31:4054-9
13. Cutuli B, Lemanski C, Fourquet A, et al. Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer 2009;100:1048-54
14. Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast-risk assessment and management options. N Engl J Med 2015;372:78-89.
15. Krishnamurthy S, Bevers T, Kuerer H, Yang WT. Multidisciplinary considerations in the management of high-risk breast lesions. AJR Am J Roentgenol 2012;198: W132-40.
16. Hartmann LC, Radisky DC, Frost MH, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) 2014;7:211-17
17. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-88
18. Chen YY, DeVries S, Anderson J, et al. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer 2009;9:285.
19. Bundred NJ, Cramer A, Morris J, et al. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res 2010;16:1605-12
20. Hwang ES, Nelson H. Reframing treatment for ductal carcinoma in situ: could less be more? Bull Am Coll Surg 2012;97:50-1
21. Kuerer HM, Buzdar AU, Mittendorf EA, et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 2011;117:39-47
22. Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011;260:119-28
23. Kurniawan ED, Rose A, Mou A, et al. Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg 2010;145:1098-104
24. Lee SK, Yang JH, Woo SY, et al. Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast. Br J Surg 2013;100:1756-63
25. Park HS, Kim HY, Park S, et al. A nomogram for predicting underestimation of invasiveness in ductal carcinoma in situ diagnosed by preoperative needle biopsy. Breast 2013;22:869-73
26. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005;200:516-26
27. Allegra CJ, Aberle DR, Ganschow P, et al. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements 2009;26:1-27
28. Pilewskie M, Kennedy C, Shappell C, et al. Effect of MRI on the management of ductal carcinoma in situ of the breast. Ann Surg Oncol 2013;20:1522-9
29. Nori J, Meattini I, Giannotti E, et al. Role of preoperative breast MRI in ductal carcinoma in situ for prediction of the presence and assessment of the extent of occult invasive component. Breast J 2014;20:243-8
30. Meyerson AF, Lessing JN, Itakura K, et al. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast 2011;20: 529-33
31. Francis A, Fallowfield L, Rea D. The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol (R Coll Radiol) 2015;27:6-8
32. McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 2015;33(7):709-15
33. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013;105: 701-10
34. Rakovitch E N-MS, Hanna W, Baehner FL, et al. A Population-Based Validation Study of the DCIS Score Predicting Recurrence Risk in Individuals Treated by Breast-Conserving Surgery. Paper presented at: San Antonio Breast Cancer Symposium; December 9-13, 2014. San Antonio, TX; 2014; Abstract S5-04
35. EORTC Ongoing and Future Projects. Available at www.eortc.org/research-groups/breast-cancer-group/ongoing-and-future-projects [Last accessed April 19, 2015]
36. Rauch GM, Kuerer HM, Scoggins ME, et al. Clinicopathologic, mammographic, and sonographic features in 1, 187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat 2013;139:639-47
37. Yao K, Czechura T, Liederbach E, et al. Utilization of accelerated partial breast irradiation for ductal carcinoma in situ, 2003-2011: report from the national cancer database. Ann Surg Oncol 2014;21:3457-65
38. Fallowfield L, Francis A, Catt S, et al. Time for a low-risk DCIS trial: harnessing public and patient involvement. Lancet Oncol 2012;13:1183-5